# A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Source: https://onco.cc/trials/nct07419295/  
OnCo record `nct07419295` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sacituzumab tirumotecan, Vinflunine and Docetaxel in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) is a phase 3 interventional study registered as NCT07419295 by Merck Sharp & Dohme LLC, with 590 participants planned, started 2026-04-23 and due to reach its primary completion in 2029-07-27. Interventions recorded: Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan and Rescue medications for chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07419295
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 590

## Sources

- ClinicalTrials.gov NCT07419295: https://clinicaltrials.gov/study/NCT07419295

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/), [Vinflunine](https://onco.cc/drugs/vinflunine/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07419295.json